iVascular is exhibiting at CIRSE 2026 in Booth D49 in Copenhagen.
Public source
Publisher name
Public post
We’re at CIRSE 2026! Our team is ready to welcome you in Copenhagen. Visit us at Booth D49 to discover our solutions, exchange experiences with our team and explore how…
Company
iVascular
Therapies for living.
- Industry
- Medical Equipment Manufacturing
- Location
- Freiburg im Breisgau, DE
- Company size
- 201–500 employees
About iVascular
The purpose of iVascular is to provide advanced medical devices and therapies for the treatment of disorders of the cardiovascular system. Thanks to the know-how provided by our technicians and an appropriate investment in technology, iVascular has implemented a vertical integration project allowing it to produce vascular devices from basic raw materials (plastics, polymers, metals...) to the final device. iVascular possesses and develops its own technologies, which have made possible the vertical integration of each and every one of the processes involved in developing a device. In this way, we guarantee the highest quality standards in all our products. Through its direct and indirect sales network, iVascular is present in more than 80 countries around the world and provides a full range of products for interventional cardiology, endovascular procedures, and neurointervention. For more information about iVascular, please visit www.ivascular.global. If you have any questions or comments, we are ready to help you out by email at info@ivascular.global
See moreLatest activity
Latest activity from iVascular
4 signals
Research & Knowledge
iVascular presented the 1-year outcomes of the iliCo study at CIRSE 2026, showing strong results for iCover in aortoiliac occlusive disease with 96.7% fTLR and patient clinical improvement of 90.4%
Research & Knowledge
iVascular released the first data release from the OPAL study, presenting results of the OPAL premarket study evaluating Amber Liquid Embolic at CIRSE 2026.
Research & Knowledge
iVascular presented new 3-year data at CIRSE 2026 showing Luminor DCB in femoropopliteal lesions has 88.3% fTLR safety and efficacy with sustained clinical benefit over time.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
FLEX Vascular
Flex Vascular is exhibiting at the CIRSE 2026 conference at the MRV 1 meeting room in Bella Center Copenhagen, Copenhagen, on Sunday, September 6, 2026.
Presence & Recognition
Concept Medical
Concept Medical will be exhibiting at CIRSE 2026 in Copenhagen, Denmark from 5 to 9 September, with Booth #F4.
Presence & Recognition
Teleflex Vascular Intervention
Teleflex Vascular Intervention is attending the CIRSE 2026 conference from 5 to 8 September.
Presence & Recognition
BIOTRONIK
BIOTRONIK is exhibiting at the CIRSE 2026 congress in Copenhagen on September 5-9 to test Zero-Gravity.
Presence & Recognition
CQ Medical